HDAC6: A unique HDAC family member as a cancer target

• Published in: Cellular oncology (Dordrecht) Vol. 45; no. 5; pp. 779 - 829
• Main Authors: Kaur, Sumeet, Rajoria, Prerna, Chopra, Madhu
• Format: Journal Article
• Language: English
• Published: Dordrecht Springer Netherlands 01.10.2022; Springer Nature B.V
• Subjects: Animals; Antineoplastic Agents - pharmacology; Antitumor agents; Apoptosis; Biomedical and Life Sciences; Biomedicine; Cancer; Cancer Research; Carcinogenesis; Cell proliferation; Cell survival; DNA damage; Drugs; Histone deacetylase; Histone Deacetylase 6 - genetics; Histone Deacetylase 6 - metabolism; Histone Deacetylase Inhibitors - pharmacology; Localization; Mice; Neoplasms - genetics; Oncology; Pathology; Proteasome Inhibitors; Review; Senescence; Tumorigenesis; Signaling pathways; Tumorigenesis; Combination therapy; HDAC6; Cancer
• ISSN: 2211-3428; 2211-3436
• DOI: 10.1007/s13402-022-00704-6

Background HDAC6, a structurally and functionally distinct member of the HDAC family, is an integral part of multiple cellular functions such as cell proliferation, apoptosis, senescence, DNA damage and genomic stability, all of which when deregulated contribute to carcinogenesis. Among several HDAC family members known so far, HDAC6 holds a unique position. It differs from the other HDAC family members not only in terms of its subcellular localization, but also in terms of its substrate repertoire and hence cellular functions. Recent findings have considerably expanded the research related to the substrate pool, biological functions and regulation of HDAC6. Studies in HDAC6 knockout mice highlighted the importance of HDAC6 as a cell survival player in stressful situations, making it an important anticancer target. There is ample evidence stressing the importance of HDAC6 as an anti-cancer synergistic partner of many chemotherapeutic drugs. HDAC6 inhibitors have been found to enhance the effectiveness of conventional chemotherapeutic drugs such as DNA damaging agents, proteasome inhibitors and microtubule inhibitors, thereby highlighting the importance of combination therapies involving HDAC6 inhibitors and other anti-cancer agents. Conclusions Here, we present a review on HDAC6 with emphasis on its role as a critical regulator of specific physiological cellular pathways which when deregulated contribute to tumorigenesis, thereby highlighting the importance of HDAC6 inhibitors as important anticancer agents alone and in combination with other chemotherapeutic drugs. We also discuss the synergistic anticancer effect of combination therapies of HDAC6 inhibitors with conventional chemotherapeutic drugs.